Clinical Trial Update: Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 open-label pilot evaluating switching virologically suppressed HIV-1 patients from raltegravir plus emtricitabine/tenofovir DF to the single-tablet regi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Isentress (Raltegravir)
• Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immunodeficiency Syndrome, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2015-01-26